- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4196 - 1,2,4-Triazoles
Patent holdings for IPC class A61K 31/4196
Total number of patents in this class: 2967
10-year publication summary
|
192
|
163
|
206
|
209
|
203
|
179
|
161
|
153
|
182
|
175
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Synta Pharmaceuticals Corp. | 173 |
77 |
| Axsome Therapeutics, Inc. | 275 |
70 |
| F. Hoffmann-La Roche AG | 7946 |
49 |
| Novartis AG | 10685 |
48 |
| Karyopharm Therapeutics Inc. | 141 |
38 |
| Genentech, Inc. | 4014 |
31 |
| Merck Sharp & Dohme LLC | 3737 |
31 |
| Hoffmann-La Roche Inc. | 3504 |
30 |
| Bayer Pharma AG | 1054 |
30 |
| Boehringer Ingelheim International GmbH | 4632 |
29 |
| Ardea Biosciences, Inc. | 71 |
27 |
| Gilead Sciences, Inc. | 2064 |
27 |
| Bristol-myers Squibb Company | 4847 |
24 |
| Pfizer Inc. | 3379 |
23 |
| The Regents of the University of California | 20195 |
21 |
| Eli Lilly and Company | 3882 |
20 |
| Bayer AG | 3380 |
19 |
| BASF SE | 21071 |
18 |
| Board of Regents, The University of Texas System | 5906 |
18 |
| Havah Therapeutics Pty Ltd | 19 |
18 |
| Other owners | 2319 |